Living Rheum
Dedicated to uncovering clinical developments and treatment advancements in the field of rheumatology, Living Rheum delivers expert insights on patient management across a broad spectrum of rheumatic diseases, such as rheumatoid arthritis, lupus, scleroderma, osteoporosis, and more.
1-15 of 92
Choosing a JAK Inhibitor for Rheumatoid Arthritis
Living RheumChoosing a JAK Inhibitor for Rheumatoid Arthritis
Roy Fleischmann, MD, MACR
Shared Decision-Making in Rheumatoid Arthritis Care
Living RheumShared Decision-Making in Rheumatoid Arthritis Care
Elena Myasoedova, MD, PhD
Beyond the Black Box: JAK Inhibitor Safety in RA
Living RheumBeyond the Black Box: JAK Inhibitor Safety in RA
Roy Fleischmann, MD, MACR
Nancy Carteron, MD
The Spectrum of Neurologic Conditions in Sjögren's Patients
Living RheumThe Spectrum of Neurologic Conditions in Sjögren's Patients
Nancy Carteron, MD
What's Next for Sjögren's Disease Treatment?
Living RheumWhat's Next for Sjögren's Disease Treatment?
Nancy Carteron, MD
- advertisement
IFNα Is Associated with a Distinct Immune Endotype in Sjögren’s Disease
Living RheumIFNα Is Associated with a Distinct Immune Endotype in Sjögren’s Disease
How Delayed Diagnosis Can Affect Psoriatic Arthritis Patients
Living RheumHow Delayed Diagnosis Can Affect Psoriatic Arthritis Patients
Philip Mease, MD, MACR
Improving Psoriatic Arthritis Diagnosis: The Role of Education
Living RheumImproving Psoriatic Arthritis Diagnosis: The Role of Education
Philip Mease, MD, MACR
The Potential Role of GLP-1s in Psoriatic Arthritis Management
Living RheumThe Potential Role of GLP-1s in Psoriatic Arthritis Management
Philip Mease, MD, MACR
Recognizing Loss of Treatment Response in Psoriatic Arthritis
Living RheumRecognizing Loss of Treatment Response in Psoriatic Arthritis
Philip Mease, MD, MACR
Emerging Therapeutic Approaches for Psoriatic Arthritis
Living RheumEmerging Therapeutic Approaches for Psoriatic Arthritis
Philip Mease, MD, MACR
- advertisement
SGLT2 Inhibitors Linked to Lower RA Risk Versus Sulfonylureas in T2D
Living RheumSGLT2 Inhibitors Linked to Lower RA Risk Versus Sulfonylureas in T2D
Targeting Celastrol Delivery to Inflamed Joints in Rheumatoid Arthritis
Living RheumTargeting Celastrol Delivery to Inflamed Joints in Rheumatoid Arthritis
How Obesity Influences Psoriatic Arthritis Risk and Outcomes
Living RheumHow Obesity Influences Psoriatic Arthritis Risk and Outcomes
Philip Mease, MD, MACR
